{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiebjh6kdlcskrrzu3oqfjowj5na7iycgzv7wtpb6qjexkm342u6d4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3misz6cfgpii2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihzqwjq5gevc7mep3gg2jnmekkenqtd3di42366qhqqgjxkrqzmbu"
    },
    "mimeType": "image/jpeg",
    "size": 119442
  },
  "path": "/2026/04/06/fda-delay-cited-in-closure-kezar-life-sciences-biotech-startup/?utm_campaign=rss",
  "publishedAt": "2026-04-06T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "drug development",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The agreement came four months too late.",
  "title": "STAT+: How a four-month FDA delay forced a small biotech company to close its doors",
  "updatedAt": "2026-04-05T17:34:09.000Z"
}